Navigating Patent Protection Beyond U.S. Borders – Key International Differences

For a life sciences startup accustomed to the United States patent system, venturing into international patent prosecution can feel like stepping into a series of parallel legal universes — each one recognizably similar in broad outline but meaningfully different in the rules, standards, and practices that determine whether a patent application succeeds or fails. These differences are not merely procedural technicalities. They can affect whether a startup’s core technology receives meaningful protection in a given market, how broadly claims can be drafted, what prior art can be cited against an application, and how long and expensive the prosecution process will be. Because life sciences companies typically need to protect their innovations in multiple major markets simultaneously — the United States, Europe, Japan, and China together represent the vast majority of global pharmaceutical and medical device revenues — understanding the key differences between these systems is an important part of building a patent strategy that delivers real commercial value across all of them.

The European Patent System: A Unified but Distinctive Approach

The European patent system operates through the European Patent Office (EPO), which examines and grants patents on behalf of its member states under a unified set of rules. A single granted European patent can then be validated in individual member states, providing national-level protection across multiple countries through a single prosecution process — a significant efficiency compared to filing separately in each country. However, the EPO applies substantive examination standards that differ from those of the USPTO in important ways, and life sciences applicants in particular will encounter distinctions that require careful attention. The EPO applies a strict prohibition on patents for methods of treatment of the human or animal body by surgery or therapy, and methods of diagnosis practiced on the human or animal body — a provision that has no direct equivalent in U.S. patent law, where method of treatment claims are routinely granted. This does not mean that pharmaceutical and medical innovations cannot be protected in Europe, but it does mean that claims must be carefully drafted to fall within recognized exceptions, such as claims directed to substances or compositions for use in a method of treatment, which the EPO does allow. Navigating these distinctions requires patent counsel with specific life sciences expertise.

The Problem-Solution Approach to Obviousness in Europe

Perhaps the single most important procedural difference between European and U.S. patent prosecution is the EPO’s use of the problem-solution approach to assess inventive step — the European equivalent of the U.S. non-obviousness requirement. Rather than asking broadly whether the differences between an invention and the prior art would have been obvious to a skilled person, as U.S. law does, the EPO applies a structured analytical framework that proceeds in defined steps. The examiner first identifies the closest single piece of prior art — the reference that most closely resembles the claimed invention. The examiner then determines the objective technical problem that the invention solves relative to that closest prior art, based on the technical effect demonstrated in the application. Finally, the examiner asks whether a skilled person, starting from the closest prior art and seeking to solve that objective technical problem, would have arrived at the claimed invention in an obvious manner. This framework has significant practical implications for how life sciences patent applications should be drafted and argued. The technical effect achieved by the invention — and the experimental data supporting it — must be clearly articulated in the application as filed, because the EPO generally will not allow applicants to rely on post-filing data to establish an effect that was not disclosed in the original application. For startups filing European applications early in their development, before all experimental results are available, this requirement makes the quality and completeness of the initial filing especially critical.

China: A Growing and Increasingly Sophisticated IP Jurisdiction

China has undergone a remarkable transformation as a patent jurisdiction over the past two decades, evolving from a system that was widely viewed with skepticism by foreign patent holders into one of the most active and increasingly sophisticated patent environments in the world. For life sciences startups, China represents both a major commercial opportunity and a jurisdiction with distinctive rules that require specific attention. The China National Intellectual Property Administration examines patent applications under substantive standards that share broad similarities with other major offices but differ in important respects. China does not permit method of treatment claims — a restriction similar in effect to the European prohibition, meaning that pharmaceutical innovations must be protected through claims directed to compounds, compositions, or medical uses rather than methods of treating patients. China also applies strict enablement and written description standards, and examiners frequently raise objections based on insufficient experimental support, particularly for broad claims in the pharmaceutical and biotechnology fields. The Chinese patent system also places significant emphasis on the data and examples provided in the application as originally filed, making it important to include robust experimental support at the time of filing rather than relying on the ability to supplement the record later.

China: Enforcement, Strategy, and Recent Reforms

Beyond the examination process itself, life sciences startups need to understand several additional dimensions of the Chinese patent landscape. Patent enforcement in China has improved substantially in recent years, with the establishment of specialized intellectual property courts and a growing body of case law that provides greater predictability for patent holders. Chinese courts have demonstrated increasing willingness to grant injunctions and meaningful damages awards in patent infringement cases, and the perception that Chinese IP protection is unenforceable in practice is considerably less accurate today than it was a decade ago. At the same time, China has developed its own robust domestic pharmaceutical and biotechnology industry, and the patent landscape in many life sciences technology areas is increasingly competitive, with both domestic and foreign players building substantial portfolios. For a startup considering its China strategy, this means that FTO analysis in the Chinese market deserves the same attention as in the United States and Europe, and that building a China patent position early — before the technology becomes widely known — is important both for protection and for negotiating leverage. Recent legislative reforms have also extended patent term restoration for pharmaceutical products in China, bringing the system closer in this respect to the frameworks that exist in the United States and Europe, and making China an increasingly important jurisdiction for life sciences patent strategy.

Japan: Precision, Clarity, and a Distinctive Examination Culture

The Japan Patent Office is widely regarded as one of the most rigorous and meticulous patent examination bodies in the world, and prosecution before the JPO has a distinctive character that reflects both the legal framework and the examination culture of the institution. Japanese patent law requires that claims be supported by detailed disclosure in the specification, and JPO examiners are known for raising support and enablement objections with a level of precision and specificity that can exceed what applicants encounter at other major offices. Claims that are drafted broadly relative to the examples and data provided in the specification are particularly vulnerable to rejection in Japan, and applicants who have become accustomed to the relatively broad claiming strategies that are sometimes successful in the United States may find that significant narrowing is required to achieve grant in Japan. For life sciences startups, this means that the Japanese prosecution strategy should be considered at the drafting stage of the original application, ensuring that the specification contains sufficient detail and experimental support to underpin the scope of protection being sought.

Japan: Prosecution Strategy and Practical Considerations

Several additional features of the Japanese patent system are worth understanding for life sciences applicants. Japan requires that a request for examination be filed within three years of the application’s filing date — a deadline that must be actively managed, as the application will lapse if the examination request is not made in time. The JPO also has a practice of issuing detailed and technically substantive office actions and responding effectively requires patent counsel with deep expertise in both the legal standards and the specific technology area. On the positive side, the JPO has invested significantly in reducing examination backlogs in recent years, and prosecution timelines have improved. Japan also offers accelerated examination programs for applicants who can demonstrate urgency. From a claim drafting perspective, it is worth noting that Japanese patent law distinguishes between product claims and use claims in ways that can affect the scope of protection available for pharmaceutical innovations, and working with experienced patent counsel to optimize claim structure for the JPO examination environment is a worthwhile investment. A patent that survives JPO examination tends to be a well-tested and defensible asset, and the Japanese market — as both a major pharmaceutical market in its own right and a gateway to broader Asian commercial opportunities — makes achieving strong protection there a priority for most life sciences companies with global ambitions.

Canada: Familiar Framework, Distinctive Rules

Canada is frequently underestimated as a patent jurisdiction by life sciences startups, perhaps because its proximity to the United States and the broad similarities between the two legal systems create an impression that Canadian prosecution is straightforward. In practice, the Canadian Intellectual Property Office applies standards that diverge from the USPTO in several important respects, and life sciences applicants will encounter unique challenges. Canada does not permit method of treatment claims, aligning it in this respect with Europe and China rather than the United States, and Canadian examiners will require that therapeutic innovations be claimed as compounds, compositions, or uses rather than as methods of treating patients. Canada also applies a distinctive utility requirement, historically interpreted to require either demonstrated utility or a sound prediction of utility based on a disclosed factual basis and sound line of reasoning at the time of filing — a standard that has created challenges for pharmaceutical patent applicants seeking broad claims based on early-stage data. Canadian courts have engaged in significant litigation over these utility standards in the pharmaceutical context, and the resulting case law creates a landscape that requires careful navigation. Canada is also notable for its Patented Medicine Prices Review Board, a regulatory body that oversees the pricing of patented medicines — a dimension of the Canadian market that intersects with patent strategy in ways that have no direct US equivalent and that bear consideration when planning a Canadian commercialization strategy.

Australia: A Welcoming but Evolving Jurisdiction

Australia has traditionally been considered a relatively patent-friendly jurisdiction, with examination standards that have historically been somewhat more permissive than those of the EPO or JPO, and a legal system that shares common law foundations with both the United States and the United Kingdom. IP Australia, the country’s patent office, examines applications under standards that allow method of treatment claims — unlike Europe, China, Japan, and Canada — making it one of the more accommodating jurisdictions for life sciences claim drafting in this respect. However, the Australian patent landscape has been evolving, and a series of court decisions and legislative reforms over the past decade have introduced greater complexity, particularly in the areas of patentable subject matter and inventive step. Australian courts have grappled with questions about the patentability of naturally occurring biological materials and diagnostic methods in ways that parallel the US Section 101 debates, and the law in this area continues to develop. Australia has also implemented a tiered patent system that includes both standard patents and innovation patents — though the innovation patent system has been phased out for new filings — and the standards for inventive step applicable to standard patents have been raised in recent years to bring them closer to international norms. For life sciences startups targeting the Australian and broader Asia-Pacific markets, Australia remains an important filing jurisdiction, and its relatively streamlined prosecution process and English-language system make it an accessible one, if applicants are attentive to the evolving standards.

Brazil: A Critical but Challenging Emerging Market

Brazil represents the largest pharmaceutical market in Latin America and one of the most significant emerging market opportunities globally for life sciences companies. However, patent prosecution in Brazil is among the most challenging of any major jurisdiction, and startups need to approach it with realistic expectations and careful planning. The Brazilian Patent Office, known by its Portuguese acronym INPI, has historically suffered from severe examination backlogs — prosecution timelines of ten years or more from filing to grant have not been uncommon, a delay that can consume a substantial portion of a patent’s effective life before it is even granted. While INPI has undertaken reforms in recent years to address these backlogs and improve examination quality, Brazil remains a jurisdiction where patience and long-term planning are essential. Brazilian patent law also applies stringent patentability standards in the pharmaceutical sector, including a requirement that pharmaceutical patents be reviewed by the Brazilian health regulatory agency ANVISA before grant — a dual approval process that adds an additional layer of complexity and delay. Brazil’s industrial property law has historically been interpreted to limit patent protection for new forms or new uses of known substances unless they demonstrate enhanced efficacy, a standard that has created obstacles for certain categories of pharmaceutical patent claims. Despite these challenges, the scale of the Brazilian market and its growing importance as a commercialization territory make establishing a patent position there worthwhile for most life sciences companies with Latin American ambitions, provided the strategy is built around realistic timelines and the guidance of experienced Brazilian IP counsel.

Building a Coherent International Strategy

The differences between patent systems — spanning the United States, Europe, Japan, China, Canada, Australia, and Brazil, as well as the many additional jurisdictions that may be relevant depending on a startup’s specific technology and commercial plans — underscore the importance of approaching international patent prosecution as a unified strategy rather than a series of independent filings. A patent portfolio that is strong in the United States but poorly constructed for the EPO’s problem-solution approach, or that lacks the experimental support needed to satisfy the JPO or China’s enablement standards, or that fails to anticipate Canada’s utility requirements or Brazil’s pharmaceutical patentability standards, will leave meaningful gaps in a company’s global IP position. The most effective approach is to build these international considerations into the patent drafting process from the very beginning — ensuring that applications are filed with sufficient data, clearly articulated technical effects, and claim structures that can be adapted for different examination environments without sacrificing commercial breadth. Working with a coordinated team of patent counsel across jurisdictions, guided by a coherent international prosecution strategy aligned with the company’s commercial priorities, is one of the most valuable investments a life sciences startup can make in its long-term competitive position.

This article is part of our Life Sciences Startup IP Resource Center.